Which adrenergic receptor causes lipolysis?
Table of Contents
Which adrenergic receptor causes lipolysis?
β-adrenergic receptors
Catecholamines stimulate lipolysis via the activation of β-adrenergic receptors in target tissues, mainly adipose tissue and muscle (23, 39). The catecholamines, epinephrine (E) and norepinephrine (NE), bind to both the lipolytic β-adrenergic receptors and the antilipolytic α2-adrenergic receptors (24).
What do beta 1 adrenergic receptors respond to?
A. Beta-1-adrenergic receptors regulate heart rate and myocardial contractility, but in situations of stress with the provocation of epinephrine release stimulation of cardiac beta-2 receptors contribute to additional increases in heart rate and contractility.
What are the effects of a beta 2 receptor agonist?
β2 adrenergic agonists’ effects on smooth muscle cause dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin. They are primarily used to treat asthma and other pulmonary disorders, such as Chronic obstructive pulmonary disease (COPD).
What do alpha 1 and 2 receptors do?
Alpha 1 receptors are the classic postsynaptic alpha receptors and are found on vascular smooth muscle. They determine both arteriolar resistance and venous capacitance, and thus BP. Alpha 2 receptors are found both in the brain and in the periphery. In the brain stem, they modulate sympathetic outflow.
Which effect is a result of beta-1 adrenergic receptor stimulation?
Targeted activation of the beta-1 receptor in the heart increases sinoatrial (SA) nodal, atrioventricular (AV) nodal, and ventricular muscular firing, thus increasing heart rate and contractility. With these two increased values, the stroke volume and cardiac output will also increase.
What type of receptor is beta-2?
Beta-2 adrenergic receptors
Beta-2 adrenergic receptors are cell-surface receptors clinically taken advantage of in the management of bronchospasm as in patients with bronchial asthma and chronic obstructive pulmonary disease. Medications targeting these receptors are either agonistic or antagonistic.
